Pharmaceutical Companies

The complexities of dealing with chronic Chagas disease (CCD) in Latin America extend beyond health, with communities grappling with significant economic challenges. Though the...

In November 2025, the Paediatric Committee (PDCO) convened to discuss the progress and status of various paediatric investigation plans and compliance checks, revealing a...

Ipsen has taken another significant step in addressing neurological conditions by presenting new data at the TOXINS 2026 conference in Madrid, Spain. Their presentation...

In a bold move to address the expanding needs of dry eye sufferers, TheraTears® has unveiled two groundbreaking products aimed at enhancing ocular comfort...

Sanofi has reaffirmed its dedication to addressing critical healthcare needs in China by unveiling two pioneering drugs—Myqorzo and Redemplo. These medications, targeting obstructive hypertrophic...

Sobi®, a leader in the biopharmaceutical sector, has delivered impressive financial results for the year 2025, reflecting strong sales momentum. Fuelled by substantial unexpected...

In a significant stride towards making healthcare more affordable in the United States, AbbVie has entered into a landmark agreement with the Trump administration....

Collegium Pharmaceutical unveils promising financial forecasts for 2026, building on their landmark achievements from the previous year. The company stands poised at the forefront...

Anticipation builds as ALK, a leading pharmaceutical entity in allergy immunotherapy, gears up to share its latest advancements at the upcoming J.P. Morgan Healthcare...

In the heart of the bustling pharmaceutical sector, ANI Pharmaceuticals, Inc. is gearing up to make a significant impact at the prestigious J.P. Morgan...

In an ever-evolving landscape where biotechnology meets pharmaceuticals, Zai Lab stands out as a pivotal player. Based in both the bustling metropolis of Shanghai...

Amgen is making a bold move in the fight against acute myeloid leukemia (AML) with its acquisition of British firm Dark Blue Therapeutics. The...

GSK has announced a breakthrough in the fight against chronic hepatitis B (CHB) with its investigational drug bepirovirsen. The company's two large-scale phase III...

A significant milestone has been reached in the treatment options available for severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) in Japan. GSK's...

The latest approval of GSK’s Nucala marks a significant milestone in China's healthcare landscape. As a nation grappling with chronic obstructive pulmonary disease (COPD),...